News stories about Alnylam Pharmaceuticals (NASDAQ:ALNY) have trended somewhat positive recently, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.963241951208 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Alnylam CEO responds to Trump: ‘I’m proud to be a ‘s***holer!’’ (finance.yahoo.com)
- Familial Amyloid Neuropathies – Pipeline Review| Therapeutics Development by Leading Key Players: Alnylam … – Medgadget (blog) (medgadget.com)
- Alnylam Pharmaceuticals, Inc. (ALNY) : Investor is seeking for stock with consensus Analysts Rating? – Wall Street Morning (wallstreetmorning.com)
- This Is Why Alnylam Pharmaceuticals Soared 249% in 2017 – Motley Fool (fool.com)
- Charity That Gets Money From Pharma To Help Patients Buy Drugs Sues Feds’ Over ‘Oppressive Restrictions’ (khn.org)
A number of research analysts recently commented on ALNY shares. Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $62.00 to $163.00 in a research note on Monday, October 2nd. Jefferies Group raised their price objective on shares of Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday, September 26th. B. Riley lowered their price objective on shares of Alnylam Pharmaceuticals to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, November 8th. Needham & Company LLC raised their price objective on shares of Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, September 20th. Finally, Cowen reiterated an “outperform” rating and set a $117.00 price objective (up previously from $93.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 20th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $121.20.
Shares of Alnylam Pharmaceuticals (ALNY) traded up $1.02 during trading hours on Friday, reaching $129.07. 796,481 shares of the company were exchanged, compared to its average volume of 1,060,000. The company has a market capitalization of $12,690.00, a PE ratio of -24.58 and a beta of 2.98. Alnylam Pharmaceuticals has a 1 year low of $35.98 and a 1 year high of $147.63. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The business had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company’s quarterly revenue was up 24.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.21) earnings per share. research analysts predict that Alnylam Pharmaceuticals will post -5.21 earnings per share for the current fiscal year.
In related news, VP Michael Mason sold 36,745 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the sale, the vice president now directly owns 6,352 shares in the company, valued at $835,859.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the sale, the executive vice president now owns 45,201 shares of the company’s stock, valued at $5,490,113.46. The disclosure for this sale can be found here. Insiders have sold 274,075 shares of company stock valued at $35,356,089 over the last 90 days. 4.30% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Alnylam Pharmaceuticals (ALNY) Share Price” was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2018/01/13/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-alnylam-pharmaceuticals-alny-share-price.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.